SCHEMBL3404353

SCHEMBL3404353

CCN(C(=O)Oc1ccc(-c2cc(O)no2)cc1)c1ccc2nc(S)sc2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
BCHE P06276 3/20 0.33
ACHE P22303 3/20 0.33
THRB P10828 2/20 0.33
SMN1; SMN2 Q16637 5/20 0.32
NPC1 O15118 4/20 0.32
RAB9A P51151 4/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPK1 P28482 2/20 0.32
SMPD1 P17405 1/20 0.32
HPGD P15428 2/20 0.32
RECQL P46063 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404268 0.90 HPGD (0.34) TP53MAPTLMNATHRBSMN1; SMN2
SCHEMBL3405819 0.88 MAPT (0.34) TP53MAPTLMNABCHEACHE
SCHEMBL3403697 0.86 TMPRSS15 (0.32)
SCHEMBL3407715 0.86 SMN1; SMN2 (0.36) TP53SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3407752 0.85 THRB (0.36) TP53MAPTLMNATHRBSMN1; SMN2
SCHEMBL3410003 0.84 MAPT (0.35) TP53MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL3408841 0.81 KMT2A (0.36) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL3406728 0.81 PDE3B (0.35)
SCHEMBL3404450 0.80 MEN1 (0.34) MAPTRAB9AKMT2A
SCHEMBL3409896 0.80 MGLL (0.37) TP53MAPTLMNATHRBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 TP53 2618/4885MAPT 3030/4885LMNA 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.